1. EMA. Advanced therapy medicinal products: overview. 15 Dec 2021. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/advanced-therapy-medicinal-products-overview
2. EMA (2021) Luxturna. Cited 15 Dec 2021. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/luxturna
3. EMA (2020) First CAR-T cell medicine for mantle cell lymphoma. 16/10/2020. Cited 2021. Available from: https://www.ema.europa.eu/en/news/first-car-t-cell-medicine-mantle-cell-lymphoma
4. Grimm D, Kleinschmidt JA (1999) Progress in adeno-associated virus type 2 vector production: promises and prospects for clinical use. Hum Gene Ther 10(15):2445–2450
5. Mietzsch M et al (2020) Characterization of AAV-specific affinity ligands: consequences for vector purification and development strategies. Mol Ther Methods Clin Dev 19:362–373